- Terms of use
- Privacy Notice
- Accessibility
- Cookie Policy
- ©2024 Freeline
Chris Hollowood
Chairman of the Board of Directors
Chris Hollowood, PhD has been the Chairman of our Board of Directors since December 2015 and served as our Executive Chairman from June 2019 to June 2020. He also serves as the Chief Executive Officer of Syncona Investment Management Limited, part of Syncona Limited, a leading healthcare investment company focused on creating, building and scaling a portfolio of global leaders in life science.
In his role at Syncona, Dr. Hollowood has been instrumental in the foundation and development of Syncona’s gene therapy strategy. In addition to Freeline, Dr. Hollowood is also Chairman at three other Syncona gene therapy companies, Beacon Therapeutics, SwanBio Therapeutics and Purespring Therapeutics. Dr. Hollowood was previously Chairman of Nightstar, a retinal gene therapy company founded by Syncona, which was sold to Biogen in 2019 for $877 million, and of Gyroscope Therapeutics, another retinal gene therapy company founded by Syncona and sold to Novartis in 2022 for up to $1.5 billion.
Previously, Chris was a partner of Apposite Capital LLP, a venture and growth capital healthcare investment company. Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry. Chris holds a degree in natural sciences and a PhD in organic chemistry, both from the University of Cambridge.
We believe Dr. Hollowood is qualified to serve on our board because of his experience as an investor in and service on the boards of other life science companies.
Connect with Chris:
We are looking for talented people to join the team